STLNW (Starling Oncology) Non Operating Income: $-2.57 Mil (TTM As of Jun. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STLNW Starling Oncology Inc STLNW
60 GF Score
Price $0.06
! 5 Warning Signs
View Full Analysis

What is Starling Oncology Non Operating Income?

Starling Oncology STLNW +3.45% 60 Non Operating Income is $-2.57 Mil as of Jun. 2026. GuruFocus rates STLNW with a GF Score™ of 60/100. The stock has 5 warning signs investors should review.

Non Operating Income is income or expense that comes from miscellaneous sources. Starling Oncology's Non Operating Income for the three months ended in Jun. 2026 was $-3.31 Mil. Its Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 was $-2.57 Mil.

Starling Oncology Non Operating Income Related Terms

Starling Oncology Non Operating Income Historical Data

* Premium members only.

The historical data trend for Starling Oncology's Non Operating Income can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Starling Oncology Non Operating Income Chart

Starling Oncology Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Non Operating Income
Get a 7-Day Free Trial 34.58 76.00 -16.18 2.95 -13.38

Starling Oncology Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Non Operating Income Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -4.06 -6.53 1.32 5.96 -3.31
STLNW
60GF Score
Starling Oncology Inc STLNW
Non Operating Income is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Starling Oncology Non Operating Income Calculation

Non Operating Income is income or expense that comes from miscellaneous sources.

Non Operating Income for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $-2.57 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Non Operating Income →
What does a Non Operating Income of $-2.57 Mil mean?
Starling Oncology (STLNW) has a Non Operating Income of $-2.57 Mil as of Jun. 2026. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Starling Oncology and its competitors.
Is Starling Oncology's Non Operating Income too high?
Starling Oncology's current Non Operating Income is $-2.57 Mil. Overall, Starling Oncology has a GF Score™ of 60/100, reflecting its overall financial health beyond just this single metric.
How does Starling Oncology's Non Operating Income compare to SRTA and CCRN?
Starling Oncology's Non Operating Income of $-2.57 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Non Operating Income for a Healthcare Providers & Services company?
A good Non Operating Income depends on the Healthcare Providers & Services industry context. However, Non Operating Income should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Non Operating Income mean?
A high Non Operating Income can signal that a stock is expensive relative to its fundamentals. Non-operating Income represents the amount of income from one-time, nonrecurring events. View historical data on Starling Oncology and its competitors. Starling Oncology's current Non Operating Income is $-2.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Starling Oncology stock overvalued right now?
Starling Oncology (STLNW) has a current Non Operating Income of $-2.57 Mil. The current Non Operating Income is $-2.57 Mil. Starling Oncology's overall GF Score™ is 60/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Non Operating Income calculated?
Non Operating Income is calculated from a company's financial statements. For Starling Oncology (STLNW), the current Non Operating Income is $-2.57 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Starling Oncology Business Description

Other Exchanges TOI:USA
Address 18000 Studebaker Road, Suite 800, Cerritos, CA, USA, 90703
The Oncology Institute Inc offers oncology care and treatment services to patients through several clinics located across the United States. It offers services such as infusion chemotherapy, oral drug chemotherapy, hospice and palliative care, autologous stem cell transplants, outpatient blood product transfusions, patient navigator programs, radiation oncology, and others on a fee or value-based model. Additionally, the company enrolls patients in clinical trials, where appropriate. The company has three operating segments: Specialty Pharmacy, Patient Services, and Clinical Trials and Other. Maximum revenue is generated from the Specialty Pharmacy segment, which operates specialty and retail pharmacies providing IV-infused, oral, injectable, and other medications for oncology treatment.
60GF Score

Get the complete analysis for STLNW

Non Operating Income is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.06
Price